-+ 0.00%
-+ 0.00%
-+ 0.00%

Atara Biotherapeutics' Pierre Fabre Pharmaceuticals Partner Refiles Tabelecleucel Biologics License Application With FDA

Benzinga·09/30/2026 12:09:19
Listen to the news

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today provided an update that its partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), has resubmitted the tabelecleucel Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).